Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

Henry Brem, M. S. Mahaley, N. A. Vick, K. L. Black, S. C. Schold, P. C. Burger, A. H. Friedman, I. S. Ciric, T. W. Eller, J. W. Cozzens, J. N. Kenealy

Research output: Contribution to journalArticle

Abstract

Malignant gliomas have been difficult to treat with chemotherapy. The most effective agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum. To obviate these problems, a method has been developed for the local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumor site allows prolonged local exposure with minimal systemic exposure. In this Phase I-II study, 21 patients with recurrent malignant glioma were treated with BCNU released interstitially by means of a polyanhydride biodegradable polymer implant. Up to eight polymer wafers were placed in the resection cavity intraoperatively, upon completion of tumor debulking. The polymer releases the therapeutic drug for approximately 3 weeks. Three increasing concentrations of BCNU were studied; the treatment was well tolerated at all three levels. There were no adverse reactions to the BCNU wafer treatment itself. The average survival period after reoperation was 65 weeks for the first dose group, 64 weeks for the second dose group, and 32 weeks for the highest dose group. The overall mean survival time was 48 weeks from reoperation and 94 weeks from the original operation. The overall median survival times were 46 weeks postimplant and 87 weeks from initial surgery. Eighteen (86%) of 21 patients lived more than 1 year from the time of their initial diagnosis and eight (38%) of 21 patients lived more than 1 year after intracranial implantation of the polymer. Frequent hematology, blood chemistry, and urinalysis tests did not reveal any systemic effect from this interstitial chemotherapy. Since the therapy is well tolerated and safe, a placebo-controlled clinical trial has been started. The trial will measure the effect of the second treatment dose on survival of patients with recurrent malignant glioma.

Original languageEnglish (US)
Pages (from-to)441-446
Number of pages6
JournalJournal of Neurosurgery
Volume74
Issue number3
StatePublished - 1991

Fingerprint

Drug Implants
Carmustine
Glioma
Polymers
Drug Therapy
Reoperation
Survival
Polyanhydrides
Therapeutics
Absorbable Implants
Urinalysis
Controlled Clinical Trials
Hematology
Half-Life
Neoplasms
Survival Rate
Placebos
Serum
Pharmaceutical Preparations

Keywords

  • BCNU
  • Biodegradable polymer
  • Brain neoplasm
  • Chemotherapy
  • Drug delivery
  • Glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Brem, H., Mahaley, M. S., Vick, N. A., Black, K. L., Schold, S. C., Burger, P. C., ... Kenealy, J. N. (1991). Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. Journal of Neurosurgery, 74(3), 441-446.

Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. / Brem, Henry; Mahaley, M. S.; Vick, N. A.; Black, K. L.; Schold, S. C.; Burger, P. C.; Friedman, A. H.; Ciric, I. S.; Eller, T. W.; Cozzens, J. W.; Kenealy, J. N.

In: Journal of Neurosurgery, Vol. 74, No. 3, 1991, p. 441-446.

Research output: Contribution to journalArticle

Brem, H, Mahaley, MS, Vick, NA, Black, KL, Schold, SC, Burger, PC, Friedman, AH, Ciric, IS, Eller, TW, Cozzens, JW & Kenealy, JN 1991, 'Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas', Journal of Neurosurgery, vol. 74, no. 3, pp. 441-446.
Brem H, Mahaley MS, Vick NA, Black KL, Schold SC, Burger PC et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. Journal of Neurosurgery. 1991;74(3):441-446.
Brem, Henry ; Mahaley, M. S. ; Vick, N. A. ; Black, K. L. ; Schold, S. C. ; Burger, P. C. ; Friedman, A. H. ; Ciric, I. S. ; Eller, T. W. ; Cozzens, J. W. ; Kenealy, J. N. / Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. In: Journal of Neurosurgery. 1991 ; Vol. 74, No. 3. pp. 441-446.
@article{0d791c3c72ef41f38c05d66eac76deb2,
title = "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas",
abstract = "Malignant gliomas have been difficult to treat with chemotherapy. The most effective agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum. To obviate these problems, a method has been developed for the local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumor site allows prolonged local exposure with minimal systemic exposure. In this Phase I-II study, 21 patients with recurrent malignant glioma were treated with BCNU released interstitially by means of a polyanhydride biodegradable polymer implant. Up to eight polymer wafers were placed in the resection cavity intraoperatively, upon completion of tumor debulking. The polymer releases the therapeutic drug for approximately 3 weeks. Three increasing concentrations of BCNU were studied; the treatment was well tolerated at all three levels. There were no adverse reactions to the BCNU wafer treatment itself. The average survival period after reoperation was 65 weeks for the first dose group, 64 weeks for the second dose group, and 32 weeks for the highest dose group. The overall mean survival time was 48 weeks from reoperation and 94 weeks from the original operation. The overall median survival times were 46 weeks postimplant and 87 weeks from initial surgery. Eighteen (86{\%}) of 21 patients lived more than 1 year from the time of their initial diagnosis and eight (38{\%}) of 21 patients lived more than 1 year after intracranial implantation of the polymer. Frequent hematology, blood chemistry, and urinalysis tests did not reveal any systemic effect from this interstitial chemotherapy. Since the therapy is well tolerated and safe, a placebo-controlled clinical trial has been started. The trial will measure the effect of the second treatment dose on survival of patients with recurrent malignant glioma.",
keywords = "BCNU, Biodegradable polymer, Brain neoplasm, Chemotherapy, Drug delivery, Glioma",
author = "Henry Brem and Mahaley, {M. S.} and Vick, {N. A.} and Black, {K. L.} and Schold, {S. C.} and Burger, {P. C.} and Friedman, {A. H.} and Ciric, {I. S.} and Eller, {T. W.} and Cozzens, {J. W.} and Kenealy, {J. N.}",
year = "1991",
language = "English (US)",
volume = "74",
pages = "441--446",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "3",

}

TY - JOUR

T1 - Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas

AU - Brem, Henry

AU - Mahaley, M. S.

AU - Vick, N. A.

AU - Black, K. L.

AU - Schold, S. C.

AU - Burger, P. C.

AU - Friedman, A. H.

AU - Ciric, I. S.

AU - Eller, T. W.

AU - Cozzens, J. W.

AU - Kenealy, J. N.

PY - 1991

Y1 - 1991

N2 - Malignant gliomas have been difficult to treat with chemotherapy. The most effective agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum. To obviate these problems, a method has been developed for the local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumor site allows prolonged local exposure with minimal systemic exposure. In this Phase I-II study, 21 patients with recurrent malignant glioma were treated with BCNU released interstitially by means of a polyanhydride biodegradable polymer implant. Up to eight polymer wafers were placed in the resection cavity intraoperatively, upon completion of tumor debulking. The polymer releases the therapeutic drug for approximately 3 weeks. Three increasing concentrations of BCNU were studied; the treatment was well tolerated at all three levels. There were no adverse reactions to the BCNU wafer treatment itself. The average survival period after reoperation was 65 weeks for the first dose group, 64 weeks for the second dose group, and 32 weeks for the highest dose group. The overall mean survival time was 48 weeks from reoperation and 94 weeks from the original operation. The overall median survival times were 46 weeks postimplant and 87 weeks from initial surgery. Eighteen (86%) of 21 patients lived more than 1 year from the time of their initial diagnosis and eight (38%) of 21 patients lived more than 1 year after intracranial implantation of the polymer. Frequent hematology, blood chemistry, and urinalysis tests did not reveal any systemic effect from this interstitial chemotherapy. Since the therapy is well tolerated and safe, a placebo-controlled clinical trial has been started. The trial will measure the effect of the second treatment dose on survival of patients with recurrent malignant glioma.

AB - Malignant gliomas have been difficult to treat with chemotherapy. The most effective agent, BCNU (carmustine), has considerable systemic toxicity and a short half-life in serum. To obviate these problems, a method has been developed for the local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumor site allows prolonged local exposure with minimal systemic exposure. In this Phase I-II study, 21 patients with recurrent malignant glioma were treated with BCNU released interstitially by means of a polyanhydride biodegradable polymer implant. Up to eight polymer wafers were placed in the resection cavity intraoperatively, upon completion of tumor debulking. The polymer releases the therapeutic drug for approximately 3 weeks. Three increasing concentrations of BCNU were studied; the treatment was well tolerated at all three levels. There were no adverse reactions to the BCNU wafer treatment itself. The average survival period after reoperation was 65 weeks for the first dose group, 64 weeks for the second dose group, and 32 weeks for the highest dose group. The overall mean survival time was 48 weeks from reoperation and 94 weeks from the original operation. The overall median survival times were 46 weeks postimplant and 87 weeks from initial surgery. Eighteen (86%) of 21 patients lived more than 1 year from the time of their initial diagnosis and eight (38%) of 21 patients lived more than 1 year after intracranial implantation of the polymer. Frequent hematology, blood chemistry, and urinalysis tests did not reveal any systemic effect from this interstitial chemotherapy. Since the therapy is well tolerated and safe, a placebo-controlled clinical trial has been started. The trial will measure the effect of the second treatment dose on survival of patients with recurrent malignant glioma.

KW - BCNU

KW - Biodegradable polymer

KW - Brain neoplasm

KW - Chemotherapy

KW - Drug delivery

KW - Glioma

UR - http://www.scopus.com/inward/record.url?scp=0026100939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026100939&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 441

EP - 446

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 3

ER -